Abstract
The tumor suppressor protein p53, once activated, can cause either cell cycle arrest or apoptosis through transactivation of target genes with p53 DNA binding sites (DBS). To investigate the role of p53 DBS in the regulation of this profound, yet poorly understood decision of life versus death, we systematically studied all known and potential p53 DBS. We analysed the DBS separated from surrounding promoter regions in yeast and mammalian assays with and without DNA damage. p53 efficiently utilized the DBS of MDM2 and of genes connected to cell cycle arrest, DNA repair and the death receptor pathway of apoptosis. However, p53 was unable to utilize two-thirds of the isolated DBS, a subset that included almost all DBS of apoptosis-related genes. Neither ASPP2, a p53-interacting protein reported to specifically stimulate p53 transcriptional activity on apoptosis-related promoters, nor DNA damage resulted in p53 utilization of isolated DBS of apoptosis-related genes. Thus, a major regulation of p53 activity occurs at the level of p53 DBS themselves by posing additional requirements for the successful utilization of apoptosis-related DBS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B . 1990 Science 249: 912–915
Bates S, Vousden KH . 1999 Cell. Mol. Life Sci. 55: 28–37
Brachmann RK, Vidal M, Boeke JD . 1996 Proc. Natl. Acad. Sci. U S A 93: 4091–4095
Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD . 1998 EMBO J. 17: 1847–1859
Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G . 2001 Oncogene 20: 3573–3579
Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M . 2002 Nat. Genet. 30: 315–320
De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G . 1998 J. Exp. Med. 188: 1763–1768
Di Como CJ, Prives C . 1998 Oncogene 16: 2527–2539
el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B . 1992 Nat. Genet. 1: 45–49
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M . 1999 Mol. Cell. Biol. 19: 2594–2600
Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T . 2002 Nature 416: 560–564
Friedlander P, Legros Y, Soussi T, Prives C . 1996 J. Biol. Chem. 271: 25468–25478
Funk WD, Pak DT, Karas RH, Wright WE, Shay JW . 1992 Mol. Cell. Biol. 12: 2866–2871
Haupt Y, Maya R, Kazaz A, Oren M . 1997 Nature 387: 296–299
Hengartner MO . 2000 Nature 407: 770–776
Hupp TR, Meek DW, Midgley CA, Lane DP . 1992 Cell 71: 875–886
Ko LJ, Prives C . 1996 Genes Dev. 10: 1054–1072
Kubbutat MH, Jones SN, Vousden KH . 1997 Nature 387: 299–303
Lane D . 2001 Nature 414: 25–26
Levine AJ . 1997 Cell 88: 323–331
Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S . 1996 Mol. Cell. Biol. 16: 6009–6019
Miyashita T, Reed JC . 1995 Cell 80: 293–299
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305
Prives C . 1998 Cell 95: 5–8
Prives C, Hall PA . 1999 J. Pathol. 187: 112–126
Rich T, Allen RL, Wyllie AH . 2000 Nature 407: 777–783
Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T, Lu X . 2001 Mol. Cell. 8: 781–794
Seol DW, Chen Q, Smith ML, Zarnegar R . 1999 J. Biol. Chem. 274: 3565–3572
Shin TH, Paterson AJ, Kudlow JE . 1995 Mol. Cell. Biol. 15: 4694–4701
Sikorski RS, Hieter P . 1989 Genetics 122: 19–27
Sionov RV, Haupt Y . 1999 Oncogene 18: 6145–6157
Szak ST, Mays D, Pietenpol JA . 2001 Mol. Cell. Biol. 21: 3375–3386
Thornborrow EC, Manfredi JJ . 1999 J. Biol. Chem. 274: 33747–33756
Thornborrow EC, Manfredi JJ . 2001 J. Biol/ Chem. 276: 15598–15608
Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW, Vogelstein B . 1994 Hum. Mol. Genet. 3: 1537–1542
Urist M, Prives C . 2002 Cancer Cell 1: 311–313
Vidal M, Brachmann RK, Fattaey A, Harlow E, Boeke JD . 1996 Proc. Natl. Acad. Sci. USA 93: 10315–10320
Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310
Vousden KH . 2000 Cell 103: 691–694
Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann RK . 2001 EMBO J. 20: 6404–6413
Yang A, Kaghad M, Caput D, McKeon F . 2002 Trends Genet. 18: 90–95
Acknowledgements
We thank WS El-Deiry, H McLeod, G Melino, M Oren and B Vogelstein for providing reagents and Nataya Boonmark for constructing the Cep4-ASPP2 plasmid. This work was supported in part by grants from the James S McDonnell Foundation and National Institutes of Health grants CA81511 (RK Brachmann) and CA76316 (L Naumouski).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qian, H., Wang, T., Naumovski, L. et al. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 21, 7901–7911 (2002). https://doi.org/10.1038/sj.onc.1205974
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205974
Keywords
This article is cited by
-
The multiple mechanisms that regulate p53 activity and cell fate
Nature Reviews Molecular Cell Biology (2019)
-
Differing tumor-suppressor functions of Arf and p53 in murine basal cell carcinoma initiation and progression
Oncogene (2017)
-
p53 pulses lead to distinct patterns of gene expression albeit similar DNA-binding dynamics
Nature Structural & Molecular Biology (2017)
-
Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers
Oncogene (2013)
-
Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy
Cell Death & Disease (2013)